In line with these findings, we show herein that triple combination with fulvestrant, CDK4/6i and another PI3K/AKT-mTOR inhibitor, AKTi, efficiently suppresses the growth of cell lines and reduces tumor progression in cell-derived and patient-derived xenografts with acquired resistance to CDK4/6i and fulvestrant combination. This evidence concerns the gene PIK3CA and neoplasm.